We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Atazanavir for HIV Infected Individuals: An Early Access Program

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00046345
Recruitment Status : No longer available
First Posted : September 30, 2002
Last Update Posted : April 14, 2011
Sponsor:
Information provided by:
Bristol-Myers Squibb

September 26, 2002
September 30, 2002
April 14, 2011
 
Atazanavir for HIV Infected Individuals: An Early Access Program
The purpose of this clinical research study is to provide atazanavir to patients infected with human immunodeficiency virus (HIV) whose antiviral medications are no longer working to control HIV activity within the body and who are unable to create a new treatment regimen using other available anti-HIV drugs, because of either side effects or treatment failure previously taken. The safety of this treatment will also be studied.
Not Provided
Expanded Access
Drug: Atazanavir (BMS-232632)
Not Provided
 
No longer available
Contact information is only displayed when the study is recruiting subjects
Puerto Rico,   United States
 
 
NCT00046345
Not Provided
Bristol-Myers Squibb
Not Provided
Not Provided
Bristol-Myers Squibb
April 2011